Robinson, D, Woerner, MG, Alvir, JJ, Bilder, R, Goldman, R, Geisler, S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry
1999; 6: 241–7.
Carpenter, WT Jr, Hanlon, TE, Heinrichs, DW, Summerfelt, AT, Kirkpatrick, B, Levine, J, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry
1990; 147: 1138–48.
Herz, MI, Glazer, WM, Mostert, MA, Sheard, MA, Szymanski, HV, Hafez, H, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry
1991; 48: 333–9.
Kane, JM, Eerdekens, M, Lindenmayer, J-P, Keith, SJ, Lesem, M, Karcher, K.
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry
2003; 160: 1125–32.
Adams, CE, Fenton, MKP, Quraishi, S, David, AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry
2001; 179: 290–9.
Rubio, G, Martinez, I, Ponce, G, Jimenez-Arriero, MA, Lopez-Munoz, F, Alamo, C.
Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry
2006; 51: 531–9.
Guy, W (1976) ECDEU Assessment Manual for Psychopharmacology: 218-22. National Institute of Mental Health, 1976.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary (55th edn) (March issue). BMJ Books & Pharmaceutical Press, 2008.
Barbee, JG, Conrad, EJ, Jamhour, NJ. The effectiveness of olanzapine, risperidone, quetiapine and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry
2004; 65: 975–81.
Centorrino, F, Fogarty, KV, Cimbolli, P, Salvatore, P, Thompson, TA, Sani, G, et al. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. J Psychiatr Pract
2005; 11: 241–7.
Shajahan, P, MacRae, A, Bashir, M, Taylor, M.
Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy. J Psychopharmacol
2008; 22: 778–83.
Stroup, TS, Lieberman, JA, McEvoy, JP, Swartz, MS, Davis, SM, Capuano, GA, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry
2007; 164: 415–27.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet
2008; 371: 1085–97.
Rabinowitz, J, Lichtenberg, P, Kaplan, Z, Mark, M, Nahon, D, Davidson, M.
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry
2001; 158: 266–9.
Tiihonen, J, Walhbeck, K, Lonnqvist, J, Klaukka, T, Ioannidis, JP, Volavka, J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ
2006; 333: 224–7.
Shajahan, P, Keith, S, Majjiga, C, Murphy, J, MacRae, A, Bashir, M, et al. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses. J Clin Psychiatry
2009; 70: 692–8.